TY - JOUR
T1 - CDK4/6 inhibitors
T2 - Game changers in the management of hormone receptor– positive advanced breast cancer?
AU - Shah, Mirat
AU - Nunes, Maria Raquel
AU - Stearns, Vered
N1 - Funding Information:
Financial Disclosure: Dr. Stearns receives research support from AbbVie, Biocept, MedImmune, Novartis, Pfizer, and Puma. Drs. Shah and Nunes have no significant financial interest in or other relationship with the manufacturer of any product mentioned in this article.
Funding Information:
Financial Disclosure: Dr. Jones has received advisory board and speaker honoraria from Janssen, as well as speaker honoraria and research funding from Sanofi Genzyme.
Funding Information:
Aramont Foundation and Canales de Ayuda Foundation for their support of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Urologic Oncology Clinic research projects.
Funding Information:
Acknowledgment: This article was supported in part through the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748.
Publisher Copyright:
© 2018, UBM Medica Healthcare Publications. All rights reserved.
PY - 2018
Y1 - 2018
N2 - The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors palbociclib, ribociclib, and abemaciclib are rapidly transformin8g the care of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer. Current clinical questions include how to choose among these agents and how to sequence them with other therapies. Areas of active inquiry include identifying predictive biomarkers for CDK4/6 inhibitors, deciding whether to continue CDK4/6 inhibitors after disease progression, creating novel treatment combinations, and expanding use beyond HR+/HER2− advanced breast cancer. Here, we review the current use of and potential next directions for CDK4/6 inhibitors in the treatment of patients with HR+ breast cancer.
AB - The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors palbociclib, ribociclib, and abemaciclib are rapidly transformin8g the care of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer. Current clinical questions include how to choose among these agents and how to sequence them with other therapies. Areas of active inquiry include identifying predictive biomarkers for CDK4/6 inhibitors, deciding whether to continue CDK4/6 inhibitors after disease progression, creating novel treatment combinations, and expanding use beyond HR+/HER2− advanced breast cancer. Here, we review the current use of and potential next directions for CDK4/6 inhibitors in the treatment of patients with HR+ breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=85050667314&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050667314&partnerID=8YFLogxK
M3 - Article
C2 - 29847850
AN - SCOPUS:85050667314
SN - 0890-9091
VL - 32
SP - 216
EP - 222
JO - ONCOLOGY (United States)
JF - ONCOLOGY (United States)
IS - 5
ER -